Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord (Q71673646)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 February 1995

Language	Label	Description	Also known as
English	Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord	scientific article published on 01 February 1995

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

M Vadillo-Buenfil

2

object named as

M Vadillo-Buenfil

1 reference

Europe PubMed Central

PubMed publication ID

20 October 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

I Cardenas-Cornejo

5

object named as

I Cardenas-Cornejo

1 reference

Europe PubMed Central

PubMed publication ID

20 October 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

author name string

D Gonzalez-Barcena

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

A Cortez-Morales

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

M Fuentes-Garcia

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

A M Comaru-Schally

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

language of work or name

0 references

publication date

1 February 1995

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

45

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

275-281

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix)

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Spinal Cord Compression from Epidural Metastases

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Prolonged duration of gonadotropin inhibition by a third generation GnRH antagonist

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Preoperative Androgen Deprivation Therapy: Artificial Lowering of Serum Prostate Specific Antigen without Downstaging the Tumor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Hormonal responses to the new potent GnRH antagonist Cetrorelix

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Spinal metastases. A retrospective survey from a general hospital

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Effectiveness of ultrasound in the preoperative evaluation of patients with prostatism

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Spinal metastases with neurological manifestations. Review of 600 cases

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Hormonal therapy of prostatic carcinoma. Defining the challenge.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Epidural spinal cord compression from metastatic tumor: diagnosis and treatment

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

How to use prostate-specific antigen

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Experiences with metastatic neoplasms involving the spinal cord

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone Agonist

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0090-4295(95)80018-2

Identifiers

10.1016/0090-4295(95)80018-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7531902%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71673646&oldid=2235593548"